StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) stock

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)

Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –

United Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

United Therapeutics's price to sales ratio was 8.1× on Nov 11, 2026, against 6.7× a year earlier. Over the last 5 years it ranged from 4.1× to 8.1×, with a median of 5.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20268.1×+1.4
2025Dec 31, 20256.7×+1.0
2024Dec 31, 20245.7×+1.0
2023Dec 29, 20234.7×−2.1
2022Dec 30, 20226.8×+0.9
2021Dec 31, 20215.9×+1.1
2020Dec 31, 20204.8×+2.2
2019Dec 31, 20192.5×−0.2
2018Dec 31, 20182.8×−1.1
2017Dec 29, 20173.8×−0.0
2016Dec 30, 20163.8×−1.2
2015Dec 31, 20155.1×+0.1
2014Dec 31, 20145.0×−0.3
2013Dec 31, 20135.3×+2.1
2012Dec 31, 20123.2×−0.7
2011Dec 30, 20113.9×−2.9
2010Dec 31, 20106.8×−1.8
2009Dec 31, 20098.6×–

More United Therapeutics figures

See a number that looks wrong?